Monthly Archives: September 2007

Haloperidol and QT prolongation and Torsades de Pointes

Posted on September 18, 2007 by admin

Johnson and Johnson and the FDA have informed healthcare professionals of the risks of sudden death, QT prolongation and Torsades de Pointes(TdP) in patients treated with haloperidol, especially when given intravenously, or at doses higher than recommended. They report: There … Continue reading →

Posted in ADRs, FDA | Comments Off

Drug Safety Update September 2007

Posted on September 5, 2007 by admin

The MHRA’s Drug Safety Update is out. This month: Hormone-replacement therapy: updated advice Tibolone: benefit-risk balance Desmopressin nasal spray: removal of nocturnal enuresis indication Pabrinex: allergic reactions Corticosteroids: early psychiatric side-effects Link to PDF.

Posted in MHRA | Comments Off

Amphotericin: Confusion between non-lipid and lipid formulations

Posted on September 3, 2007 by admin

The National Patient Safety Agency (NPSA) has issued a rapid response report Risk of confusion between non-lipid and lipid formulations of injectable amphotericin. The National Patient Safety Agency (NPSA) is alerting all healthcare staff involved in the use of intravenous … Continue reading →

Posted in Medication error | Comments Off

lumiracoxib (Prexige) and the liver

Posted on September 3, 2007 by admin

Following consultation with the MHRA and other European regulators, the manufacturer of the osteoarthritis drug lumiracoxib (Prexige), is writing to health professionals to inform them of new restrictions on the prescribing of lumiracoxib. Concern was raised worldwide after rare reports … Continue reading →

Posted in ADRs, EMEA, MHRA | Comments Off